Second line treatment for relapsed chronic lymphocytic leukemia

Giuseppe Rossi

doi:10.4081/hmr.v1i7.630

Abstracts

16 June 2009

Vol. 1 No. 7 (2007)

https://doi.org/10.4081/hmr.v1i7.630

Second line treatment for relapsed chronic lymphocytic leukemia

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

206

Views

1378

Downloads

Authors

Giuseppe Rossi

support@pagepress.org

In spite of the remarkable therapeutic achievements obtained with purine analogues and monoclonal antibodies, chronic lymphatic leukaemia (CLL) has still to be considered an incurable disease. Indeed, in the vast majority of patients, the natural history of the disease is characterized by multiple relapses and by multiple remissions, induced by the potential treatments available.